Skip to content
Disclosery

GILEAD SCIENCES, INC.

Follow

13F filer, CIK 882095, FOSTER CITY, CA

GILEAD SCIENCES, INC. reported $1,791,467,184 across 9 holdings for the quarter ended 2025-09-30, in a 13F-HR filed 2025-11-13.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001123292-25-000642

Period
2025-09-30
Reported value
$1.79B
Holdings
9
Top 10 weight
100%
New
0
Sold out
5

Part of the filer group GILEAD SCIENCES, INC.

How groups are built

Largest buys vs the previous quarter

SecurityShares changeApprox. value
ASMBadded+2,295,920$58.8M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
HOOKexited-1,875,945-$2.35M
ALLOexited-1,156,689-$1.31M
KLRSexited-317,789-$848K
IKENA ONCOLOGY INCexited-348,534-$467K
BRNSexited-99,478-$92.5K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2025

Share positions as resolved from 13F-HR 0001123292-25-000642, largest first. % of portfolio is the value over $1,791,467,184, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
LKFTLAKEFRONT BIOTHERAPEUTICS NVQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 16,707,477 shares; 2025Q1: 16,707,477 shares; 2025Q2: 16,707,477 shares; 2025Q3: 16,707,477 shares 16,707,477$579M32.31%0Timeline
ACLXARCELLX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 6,720,803 shares; 2025Q1: 6,720,803 shares; 2025Q2: 6,720,803 shares; 2025Q3: 6,720,803 shares 6,720,803$552M30.8%0Timeline
RCUSARCUS BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 30,061,124 shares; 2025Q1: 31,424,760 shares; 2025Q2: 31,424,760 shares; 2025Q3: 31,424,760 shares 31,424,760$427M23.86%0Timeline
ASMBASSEMBLY BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 2,209,471 shares; 2025Q1: 2,209,471 shares; 2025Q2: 2,209,471 shares; 2025Q3: 4,505,391 shares 4,505,391$115M6.44%+2,295,920Timeline
MERUS N VMERUS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 452,527 shares; 2025Q1: 452,527 shares; 2025Q2: 452,527 shares; 2025Q3: 452,527 shares 452,527$42.6M2.38%0
TNGXTANGO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 4,854,443 shares; 2025Q1: 4,854,443 shares; 2025Q2: 4,854,443 shares; 2025Q3: 4,854,443 shares 4,854,443$40.8M2.28%0Timeline
KYTXKYVERNA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 4,126,119 shares; 2025Q1: 4,126,119 shares; 2025Q2: 4,126,119 shares; 2025Q3: 4,126,119 shares 4,126,119$24.8M1.38%0Timeline
XLOXilio Therapeutics Inc.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 9,105,451 shares; 2025Q1: 9,105,451 shares; 2025Q2: 9,105,451 shares; 2025Q3: 9,105,451 shares 9,105,451$7.67M0.43%0Timeline
CYPHCYPHERPUNK TECHNOLOGIES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 5,319,148 shares; 2025Q1: 5,319,148 shares; 2025Q2: 5,319,148 shares; 2025Q3: 5,319,148 shares 5,319,148$2.41M0.13%0Timeline

Sold out in Q3 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
HOOKHOOKIPA PHARMA INC COM NEW1,875,945$2.35Mshares
ALLOALLOGENE THERAPEUTICS INC1,156,689$1.31Mshares
KLRSKALARIS THERAPEUTICS INC317,789$848Kshares
IKENA ONCOLOGY INCIKENA ONCOLOGY INC348,534$467Kshares
BRNSBARINTHUS BIOTHERAPEUTICS PL99,478$92.5Kshares

How Q3 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001123292-25-000642 base2025-11-13acceptance time not in the bulk data set